Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus oxycodone for protection against lower-limb tourniquet ischemia-reperfusion injury
ChiCTR1800018510Phase 4Recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine and oxycodone in ischemia-reperfusion injury (IRI) (3 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoints: Interleukin-6, Tumor necrosis factor alpha and 5 more. Started Oct 2018; status: recruiting.
02
Drugs
dexmedetomidineoxycodone
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on ChiCTR1800018510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018510.